Nordea Investment Management AB Invests $5.64 Million in Charles River Laboratories International, Inc. $CRL

Nordea Investment Management AB bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 38,078 shares of the medical research company’s stock, valued at approximately $5,636,000. Nordea Investment Management AB owned approximately 0.08% of Charles River Laboratories International at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Jones Financial Companies Lllp raised its stake in shares of Charles River Laboratories International by 167.6% in the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after buying an additional 1,074 shares in the last quarter. Empowered Funds LLC acquired a new position in Charles River Laboratories International in the first quarter worth about $418,000. Parallel Advisors LLC raised its position in Charles River Laboratories International by 29.1% in the second quarter. Parallel Advisors LLC now owns 612 shares of the medical research company’s stock worth $93,000 after purchasing an additional 138 shares in the last quarter. Czech National Bank lifted its stake in Charles River Laboratories International by 2.2% during the second quarter. Czech National Bank now owns 12,002 shares of the medical research company’s stock worth $1,821,000 after purchasing an additional 257 shares during the period. Finally, Exchange Traded Concepts LLC boosted its holdings in Charles River Laboratories International by 1.3% during the second quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company’s stock valued at $871,000 after purchasing an additional 76 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 1.6%

Shares of NYSE CRL opened at $219.81 on Friday. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $228.88. The company has a 50-day moving average of $191.81 and a two-hundred day moving average of $174.14. The company has a market cap of $10.82 billion, a PE ratio of -140.90, a P/E/G ratio of 6.57 and a beta of 1.61. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating the consensus estimate of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $990.43 million. During the same period in the prior year, the firm earned $2.59 earnings per share. Charles River Laboratories International’s revenue was down .5% compared to the same quarter last year. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CRL. William Blair raised Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Robert W. Baird set a $224.00 price objective on Charles River Laboratories International in a research note on Friday, January 9th. Citigroup lifted their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a report on Friday. Baird R W raised shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Finally, Evercore ISI lifted their price target on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus price target of $209.46.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.